Careers
About
Cardio vascular disease (CVD) is a leading cause of morbidity and mortality. Most of the deaths occur even before a patient reaches the hospital for treatment. Cardiac markers are biomarkers which are measured to evaluate the function of heart.
A number of conditions can lead to an elevation in cardiac marker level, the most important one being myocardial infarction (MI), commonly known as a heart attack. Many of the markers are enzymes; the term "cardiac enzymes" is sometimes used. However, not all the markers are enzymes. Troponin for example is not an enzyme in formal terms.
A number of conditions can lead to an elevation in cardiac marker level, the most important one being myocardial infarction (MI), commonly known as a heart attack. Many of the markers are enzymes; the term "cardiac enzymes" is sometimes used. However, not all the markers are enzymes. Troponin for example is not an enzyme in formal terms.
Aspartate Amino transferase was perhaps the first biochemical marker to be used; it was described in 1954. With the advent of electrophoresis method walked in Creatine Kinase and Lactate Dehydrogenase iso enzymes. The use of cTnT brought about a revolution in 1992. The introduction of Cardiac troponins heralded a new age in the diagnosis and treatment or management of a broad spectrum of diseases.
Latest Publications and Research on Cardiac Markers
Effect of 12 wk of resistant starch supplementation on cardiometabolic risk factors in adults with prediabetes: a randomized controlled trial. - Published by PubMedIncremental Value of Objective Frailty Assessment to Predict Mortality in Elderly Patients Hospitalized for Heart Failure. - Published by PubMed
Application of competing risks analysis improved prognostic assessment of patients with decompensated chronic heart failure and reduced left ventricular ejection fraction. - Published by PubMed
Restoration of cardiac function after anaemia-induced heart failure in zebrafish. - Published by PubMed
Association of Thrombomodulin Gene C1418T Polymorphism with Susceptibility to Kawasaki Disease in Chinese Children. - Published by PubMed
More
Advertisement
The ischemic biomarker Heart-type Fatty Acid Binding Protein [H-FABP] can substantially improve the detection of high risk patients when Troponin-negative, even when a high sensitivity assay is used, a new publication has shown. In the June edition of JACC, Professor Alistair Hall and colleagues from the University of Leeds, UK, prospectively studied a cohort of 1080 consecutive patients admitted to hospital with suspected ACS and compared the H-FABP assay (Randox Laboratories) with the high sensitivity Ultra-TnI assay (Siemens Healthcare Diagnostics).